Recent Updates in the Management of Lower-Risk Myelodysplastic Syndrome

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

In the first article of this series, Elias Jabbour, MD, gives an overview of myelodysplastic syndrome and discusses the evolving treatment landscape.

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.

Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

In the fourth article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.

Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.